CN111432845B - 保护靶向放射治疗诱导下的血管完整性的方法 - Google Patents

保护靶向放射治疗诱导下的血管完整性的方法 Download PDF

Info

Publication number
CN111432845B
CN111432845B CN201880062272.0A CN201880062272A CN111432845B CN 111432845 B CN111432845 B CN 111432845B CN 201880062272 A CN201880062272 A CN 201880062272A CN 111432845 B CN111432845 B CN 111432845B
Authority
CN
China
Prior art keywords
minutes
subject
radiation
tpo
radiation therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880062272.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111432845A (zh
Inventor
G·艾肯鲍姆
A·托内利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN111432845A publication Critical patent/CN111432845A/zh
Application granted granted Critical
Publication of CN111432845B publication Critical patent/CN111432845B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
CN201880062272.0A 2017-07-26 2018-07-26 保护靶向放射治疗诱导下的血管完整性的方法 Active CN111432845B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537049P 2017-07-26 2017-07-26
US62/537,049 2017-07-26
PCT/US2018/043821 WO2019023418A1 (en) 2017-07-26 2018-07-26 METHODS FOR PROTECTING VASCULAR INTEGRITY INDUCED BY TARGETED RADIOTHERAPY

Publications (2)

Publication Number Publication Date
CN111432845A CN111432845A (zh) 2020-07-17
CN111432845B true CN111432845B (zh) 2024-02-06

Family

ID=63165522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880062272.0A Active CN111432845B (zh) 2017-07-26 2018-07-26 保护靶向放射治疗诱导下的血管完整性的方法

Country Status (11)

Country Link
US (1) US12251424B2 (https=)
EP (1) EP3658191A1 (https=)
JP (1) JP7481252B2 (https=)
KR (1) KR102688415B1 (https=)
CN (1) CN111432845B (https=)
AU (1) AU2018306329B8 (https=)
BR (1) BR112020001367A2 (https=)
CA (1) CA3070442A1 (https=)
IL (1) IL272213A (https=)
PH (1) PH12020500166A1 (https=)
WO (1) WO2019023418A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008943A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
CN119654158A (zh) * 2022-05-20 2025-03-18 詹森药业有限公司 用于减轻与暴露于辐射和/或辐射或拟辐射治疗相关的肺损伤的方法
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
WO2025002113A1 (zh) * 2023-06-26 2025-01-02 上海济煜医药科技有限公司 一种人血小板生成素受体激动剂的融合蛋白

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040750A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
WO1998025965A2 (en) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
WO2005023834A2 (en) * 2003-08-28 2005-03-17 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to thrombopoietin receptors
CN1895276A (zh) * 2006-06-13 2007-01-17 卢建军 用于治疗血小板减少的注射用药物
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
DK1984014T3 (da) 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
CA2670345A1 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
US8383124B2 (en) 2008-03-12 2013-02-26 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
ES2729622T3 (es) 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
JP2012518408A (ja) 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
JP2012250880A (ja) 2011-06-03 2012-12-20 Semiconductor Energy Lab Co Ltd グラフェン、蓄電装置および電気機器
US20140047572A1 (en) 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US20140051631A1 (en) 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
JP6150374B2 (ja) 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
WO2020154637A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040750A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
WO1998025965A2 (en) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
WO2005023834A2 (en) * 2003-08-28 2005-03-17 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to thrombopoietin receptors
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
CN1895276A (zh) * 2006-06-13 2007-01-17 卢建军 用于治疗血小板减少的注射用药物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Anemia in Lung Cancer: Clinical Impact and Management;Robert Pirker et al.;《Clinical Lung Cancer》;20030930;第5卷(第2期);第90-97页 *
Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion;Kathleen A. Ashcraft et al.;《RADIATION RESEARCH》;20181231;第190卷;第12-21页 *
How platelets safeguard vascular integrity;D.D.WAGNER et al.;《Journal of Thrombosis and Haemostasis》;20111231;第9卷;第56-65页 *
Thrombopoietin-Mimetic Romiplostim Confers the Complete Survival Rate to Mice Exposed to Lethal Ionizing Radiation;Masaru Yamaguchi et al.;《Blood》;20151203;第126卷(第23期);摘要 *
孔宪明等主编.《心血管疾病诊疗技术》.人民卫生出版社,2001,第779-780页. *
李慧文 李航编著.血小板及其捐献与输注.《血小板及其捐献与输注》.中国科学技术出版社,2017,第15页. *

Also Published As

Publication number Publication date
AU2018306329A8 (en) 2025-02-20
WO2019023418A1 (en) 2019-01-31
AU2018306329B2 (en) 2024-09-19
JP7481252B2 (ja) 2024-05-10
KR20200059213A (ko) 2020-05-28
US12251424B2 (en) 2025-03-18
KR102688415B1 (ko) 2024-07-24
CN111432845A (zh) 2020-07-17
JP2020528903A (ja) 2020-10-01
US20200164039A1 (en) 2020-05-28
BR112020001367A2 (pt) 2020-08-11
EP3658191A1 (en) 2020-06-03
AU2018306329A1 (en) 2020-02-13
PH12020500166A1 (en) 2020-09-14
AU2018306329B8 (en) 2025-02-20
IL272213A (en) 2020-03-31
CA3070442A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CN111432845B (zh) 保护靶向放射治疗诱导下的血管完整性的方法
Chanda et al. Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nanoplatform for computer tomography theranostics
EP3914272B1 (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
Palmowski et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions
JP2022523663A5 (https=)
US20200237872A1 (en) Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
RS57524B1 (sr) Anti-alfa-v integrin antitelo za tretman kancera prostate
US20230233705A1 (en) Gold nanoparticle-containing medicine
HK40033362A (en) Methods of protecting vascular integrity induced by targeted radiation therapy
US20250312417A1 (en) Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments
Gan et al. A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Nicholson et al. 576: Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach
HK40064882A (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
Sattiraju Loco-Regionally Targeting Interleukin-13 Receptor Alpha-2 and Maximizing Therapeutic Access to Glioblastomas Using Biomarker Directed Alpha Particles
Werahera et al. 575: Proliferative Tumor Doubling Times of Prostatic Carcinoma Measured by in Vivo Bromodeoxyuridine (BRDU) Labeling and Flow Cytometric Analysis
Miyagi et al. 574: Cellular Interaction Between Prostate Cancer and Bone Stroma: Effects of Radiation on the Growth and Colonization of Human Prostate Cancer Cells in Bone
Tsopelas Jacobs Journal of Nanomedicine and Nanotechnology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033362

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant